Intrapartum chemoprophylaxis of perinatal group B streptococcal infections: a critical review of randomized controlled trials.

Am J Obstet Gynecol

University of Toronto Perinatal Clinical Epidemiology Unit, Women's College Hospital, Ontario, Canada.

Published: March 1994

The purpose of this overview was to critically appraise all published randomized, controlled trials evaluating the efficacy of intrapartum chemoprophylaxis in reducing perinatal group B streptococcal infections. The Oxford Database of Perinatal Trials, Medline, Excerpta Medica, and personal files were used for the literature search. By means of present inclusion criteria to select relevant articles, two independent researchers identified nine randomized, controlled trials. Three trials were excluded because of duplicate publication, one because the randomization process was violated, and one because the outcome data were collected retrospectively. The quality of the methods of the four accepted trials was poor, and because of basic flaws meta-analyses of trial results were not performed. Results of three studies showed a statistically significant reduction in neonatal group B streptococcal colonization rates with intrapartum chemoprophylaxis. Although a trend toward a reduction in proved neonatal infection was reported in three studies, each lacked the power to reach statistical significance. Intrapartum chemoprophylaxis to reduce perinatal group B streptococcal infections is not supported by conclusive evidence from well designed and conducted randomized, controlled trials.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0002-9378(94)70307-8DOI Listing

Publication Analysis

Top Keywords

intrapartum chemoprophylaxis
16
group streptococcal
16
randomized controlled
16
controlled trials
16
perinatal group
12
streptococcal infections
12
three studies
8
trials
7
intrapartum
4
perinatal
4

Similar Publications

Article Synopsis
  • Group B streptococcus (GBS) is a significant cause of infections in neonates and pregnant women, with Japan implementing guidelines for screening and antibiotic use, yet infections have not decreased significantly.
  • Approximately 15% of pregnant women lack GBS screening, and issues like intermittent colonization lead to early-onset disease; current preventative measures don't address increasing cases of late-onset disease.
  • This study found that using polymerase chain reaction for GBS detection was more effective than culture methods, highlighted the risk of horizontal transmission, and emphasized the need for better diagnostic tools and potential maternal vaccination for prevention.
View Article and Find Full Text PDF

Background And Objectives: The Kaiser Permanente Neonatal Early-Onset Sepsis (EOS) Calculator has been an effective tool for risk stratification to safely reduce newborn antibiotic exposure. The calculator was derived from data on infants born between 1993 and 2007. Since that time, US obstetric practice has adopted universal antepartum screening for group B Streptococcus and intrapartum antibiotic prophylaxis guidance has changed.

View Article and Find Full Text PDF

Group B streptococcus colonization in pregnancy and neonatal outcomes: a three-year monocentric retrospective study during and after the COVID-19 pandemic.

Ital J Pediatr

September 2024

Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "Giuseppe D'Alessandro", University of Palermo, Palermo, Italy.

Background: Group B Streptococcus (GBS) is a major cause of sepsis and meningitis in newborns. The Centers for Disease Control and Prevention (CDC) recommends to pregnant women, between 35 and 37 weeks of gestation, universal vaginal-rectal screening for GBS colonization, aimed at intrapartum antibiotic prophylaxis (IAP). The latter is the only currently available and highly effective method against early onset GBS neonatal infections.

View Article and Find Full Text PDF

Background: Early-onset neonatal sepsis represents a diagnostic challenge, as it is a cause of neonatal mortality and morbidity. Guidelines for the prevention of group B streptococcus (GBS) infection recommend that all pregnant women must be screened for GBS carriage at the end of pregnancy, with intrapartum antibiotic prophylaxis being provided for GBS carriers. If vaginal culture is not available, GBS polymerase chain reaction (GBS-PCR) is an alternative option for this type of screening.

View Article and Find Full Text PDF

How can we reduce neonatal sepsis after universal group B streptococcus screening?

BMC Pregnancy Childbirth

September 2024

Department of Obstetrics and Gynaecology, Hong Kong Baptist Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.

Background: Group B Streptococcus (GBS) infection remains a leading cause of newborn morbidity and mortality. The study aimed to determine the adherence rate to the universal screening policy a decade after its introduction. Secondly, whether the timing of antibiotics given in GBS carriers reduces the incidence of neonatal sepsis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!